振东制药(300158) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥782,130,269.05, a decrease of 17.79% compared to ¥951,417,159.09 in the same period last year[4] - Net profit attributable to shareholders was ¥23,101,557.95, a significant increase of 5,952.52% from a loss of ¥394,728.53 in the previous year[4] - Basic and diluted earnings per share were both ¥0.0225, a remarkable increase of 5,725.00% from -¥0.0004 in the previous year[4] - The net profit for Q1 2024 was CNY 22,347,124.36, a significant increase compared to a net loss of CNY 902,065.90 in Q1 2023, representing a turnaround in performance[31] - Operating profit reached CNY 32,289,666.48, up from CNY 7,304,228.83 in the same period last year, indicating a growth of approximately 342%[31] - The total comprehensive income for Q1 2024 was CNY 22,347,119.92, compared to a loss of CNY 891,481.36 in Q1 2023[31] Cash Flow and Assets - The net cash flow from operating activities improved by 89.22%, reaching -¥23,874,405.33 compared to -¥221,509,803.49 in the same period last year[4] - Cash and cash equivalents at the end of the period were CNY 652,192,702.52, down 18.5% from CNY 800,880,110.60 at the beginning of the period[26] - Cash and cash equivalents at the end of the period were CNY 611,247,201.40, down from CNY 709,902,818.18 at the end of Q1 2023[36] - The company's total assets decreased to CNY 5,984,487,890.46 from CNY 6,180,497,035.31, reflecting a decline of 3.2%[28] - Total liabilities decreased to CNY 902,257,438.52 from CNY 1,036,388,580.76, reflecting a decline of 13.0%[28] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 53,808, with the largest shareholder holding 29.41% of the shares[14] - The company reported a total of 302,228,291 shares held by its largest shareholder, Shanxi Zhendong Health Industry Group, accounting for 29.34% of the total share capital[19] - The total number of shares held by the top 10 unrestricted shareholders amounts to 302,228,291 shares, with the largest shareholder being Shanxi Zhendong Health Industry Group[16] - The company has 4,027,700 shares held by Liu Yubin, which constitutes 0.39% of the total shares[16] - The report shows that the company has not experienced any changes in the number of restricted shares during the reporting period, maintaining a total of 3,378,435 restricted shares[23] Investment and Income - Investment income for Q1 2024 was ¥16,888,805.04, an increase of 72.64% compared to the previous year[10] - The company recorded a significant increase in asset disposal income, which reached ¥10,207,738.19, up 12,142.74% year-on-year[10] - The company reported an investment income of CNY 16,888,805.04, an increase from CNY 9,782,844.63 in the previous period[29] Operating Costs - Total operating costs for Q1 2024 were CNY 795,147,632.83, down 18.6% from CNY 977,786,837.89 in the previous period[29] - Research and development expenses decreased to CNY 38,447,733.67, a reduction of 21.3% from CNY 48,885,568.66 in the previous period[29] - Total revenue from operating activities was CNY 800,525,339.92, a decrease of about 10.3% compared to CNY 892,116,798.41 in Q1 2023[33] Other Financial Metrics - The company experienced a foreign exchange loss of CNY 4.44 in other comprehensive income, contrasting with a gain of CNY 10,584.54 in the previous year[31] - The company incurred a credit impairment loss of -CNY 604,975.44, an improvement from -CNY 1,723,445.72 in the previous year[31] - The company has a total of 5,300,555 shares held by Hong Kong Central Clearing Limited, representing 0.52% of the total shares[16] - The report highlights that the company has not disclosed any related party relationships among the top shareholders[16] - The company’s stock structure includes a significant portion of shares held by various investment funds, indicating diversified ownership[16]